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Abstract
Introduction: Malignant peripheral nerve sheath tumors are rare soft tissue sarcomas. They are
considered to carry a poor prognosis with current therapeutic approaches. Successful treatment
depends on a multimodal approach.
Case presentation: The authors report two cases with malignant peripheral nerve sheath tumors
arising from pre-existing neurofibromas in the grounds of neurofibromatis-type I. Complete surgical
removal of all lesions is considered before and after induction chemotherapy. Correlation of the
response to chemotherapy in the context of the immuno-histopathological features of the tumors is
also discussed with reference to the existing literature.
Conclusion: A need for a multidisciplinary approach with chemotherapy, surgery and radiotherapy
is anticipated in the management of malignant peripheral nerve sheath tumors as described in these
two reported cases. It is felt that further research on the molecular aspects of malignant peripheral
nerve sheath tumors and neurofibromatis-type I will optimize treatment strategies in the future.
Introduction
Neurofibromatosis (NF) is an autosomal dominant
disorder of neural crest origin affecting all three germinal
layers. It can therefore involve in any organ system.
Clinically two distinct types are recognized; NF-type 1
(NF1), or von Recklinghausen disease affecting 85% of
patients, and NF-type 2 (NF2), or bilateral acoustic
neuromas/schwannomas affecting 10% of patients [1].
NF1 is characterized by the presence of multiple neurofi-
bromas that may affect any organ. Discrete cutaneous and/
or subcutaneous neurofibromas may develop at any age,
but they occur infrequently before adolescence, varying in
numbers from a few lesions to hundreds/thousands all
over the body, continuing to develop throughout life [2].
Neurofibromas in NF1 may undergo malignant degenera-
tion in 3% of patients. Schwannomas are composed
entirely of Schwann cells, and malignant transformation is
extremely rare; however, when it occurs, it is associated
with von Recklinghausen disease in 75% of patients. NF1
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neoplasms at any age, with a predominance of intracranial
neoplasms such as, optic tract gliomas, cerebral gliomas,
cranial nerve schwannomas, hamartomas, and craniofacial
plexiform neurofibromas [3].
Malignant peripheral nerve sheath tumors (MPNST)
constitute a heterogeneous group of malignant tumors
that probably arise from cells of the peripheral nerve
sheath and are categorized as soft tissue sarcomas with an
associated poor prognosis and in general, limited treat-
ment options. Factors contributing to tumor progression
remain largely unknown and undefined. They represent
one of the most frequent non-rhabdomyosarcomatous
soft tissue tumors in pediatric age and usually occur in
young adults from a previously anticipated plexiform
neurofibroma in the context of NF1, with a noted change
in size and pain [4]. At present there are only limited data
based on anecdotal reports regarding the occurrence of
MPNST in NF1 in children and adults [4,5]. Herein we
report two cases of adult MPNST in NF1 and emphasize




A 23-year-oldwhite female with aprevious knownhistory of
NF1 was admitted in August 2004 after having noticed a
painful, enlarging mass in her left lower leg, which rapidly
increased in size within the last two months. An MRI was
performed in December 2004 and revealed an extensive
plexiform neurofibroma in the lower leg extending from the
superior margin of the distal thigh to the ankle with areas of
cystic necrosis and hemorrhage (Figure 1). However, on the
MR appearances it was not fully possible to exclude
malignant transformation. The biopsy revealed a high-
grade spindle cell sarcoma with features consistent with a
malignant peripheral nerve sheath tumor (Figure 2).
Immunohistochemical analysis of the tumor specimen
revealed positivity for vimentin, S-100, p53, and CD56,
weak focal expression of CD117, and 20% positivity for
MIB1, whereas staining for desmin, CD34, CD57, and
topoisomerase IIa (TopoIIa) yielded negative results (Table
1). In January 2005, the patient presented to our hospital
and a chest CT revealed a second tumor in the vertebral
costal of the 11
th right rib extending to the adjoining bone
and muscles, representing a second primary tumor. She
immediately started neo-adjuvant chemotherapy with ifos-
famide 2 gm/m² and doxorubicin 60 mg/m²/day × 3 days
followedbycisplatin100mg/m²anddoxorubicin60mg/m²
every three weeks. Dose reduction in all regimens was
necessary because of grade IV neutropenia. The patient
completed four cycles and a new MRI revealed minimal
r e d u c t i o ni ns i z eo fb o t ht u m o r s ,w h i c hd i dh o w e v e r ,m a d e
surgicaloperationpossible.InApril2005,shewassubmitted
Figure 1. MRI image showing the site of the tumor in the
left tibia (Case 1).
Figure 2. Histology demonstrates a plexiform malignant
peripheral nerve sheath tumor; hematoxylin-eosin
stain × 40 (Case 1).
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bone, nerve, and vascular structures remained intact. The
biopsy confirmed the presence of an 18 cm MPNST with
pathological features of intense mitotic activity and nuclear
atypia, vascular infiltration with surgical margins being free
of tumor. The patient recovered uneventfully after surgical
removal of the leg lesion and was planned to be submitted
to a second operation for the excision of the lesion in the
chest. However, two months later she presented in the
emergency room with acute respiratory failure with chest
X-rays revealing rapid enlargement of the thoracic mass
compressing mediastinal structures. She developed a cardiac
arrest and died despite intensive resuscitation efforts.
Case Report 2
A 70-year-old white male with a previous history of NF1
was referred to our hospital in February 2003, where
physical examination revealed the typical neurofibromas
over the skin, the anterior and posterior chest and
abdominal walls and café-au-lait spots (Figure 3A) and in
addition, an ulcerated subcutaneous lesion in his upper
dorsum measuring 6 × 6 cm, that had been growing slowly
over the past year (Figure 3B). A thoracic CT scan and Tc-
99 m-depreotide scintigraphy (Neospect) were performed
revealing a second lesion in the left axillary area,
apparently representing an infiltrated lymph nodal
block. The FNA from the dorsal lesion demonstrated
malignant sarcomatous cells. The patient underwent a
surgical excision of both lesions and biopsy confirmed the
presence of a spindle cell sarcoma with features consistent
with a malignant peripheral nerve sheath tumor. A year
later, the patient was admitted to our department for his
follow-up. CT and Neospect examination indicated a
relapse in the area of both surgical excisions as well as a
new mass in the right lateral body of the first thoracic
vertebra. He started chemotherapy with carboplatin AUC6
on day one and etoposide 120 mg/m
2/day on days 1-3,
every three weeks. After the completion of eight courses
with this regimen the patient achieved stable disease (SD).
No grade 3 or 4 myelosuppression was noticed. The
patient continued chemotherapy with ifosfamide 2 gr/m
2/
day over days 1-5, alternating every three weeks with
cisplatin 100 mg/m
2 and doxorubicin 60 mg/m
2 both
administered on day one and recycled every 3 weeks ×
4 cycles. Grade 4 neutropenia was observed after cisplatin-
doxorubicin administration, however no dose reduction
was carried-out. A new radiographic evaluation performed
in May 2005 showed complete eradication of the tumors
in the dorsum and spine and a significant size reduction of
the axillary nodal block. Thereafter, the patient received
chemotherapy with carboplatin AUC2 and paclitaxel
40 mg/m
2 administered once weekly concurrently with
radiotherapy on all sites of residual disease for a total of
four weeks. After the end of chemoradiation, complete
remission (CR) was achieved. Eight months later, the
patient developed multiple lung metastases and dyspnea.
He was not subjected to further chemotherapy and died
from progressive disease in the lung.












Figure 3. (A) Multiple cutaneous neurofibromas over the
anterior thoracic and abdominal wall and café-au-lait spots
characteristic of neurofibromatosis type-1 (NF1) and an
axillary tumor. (B) Multiple cutaneous neurofibromas and
café-au-lait spots over the dorsum and an ulcerating mass, which
on biopsy revealed sarcomatous transformation (Case 2).
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Malignant peripheral nerve sheath tumor (MPNST)
represents a dramatic complication of NF1 and approxi-
mately 2-5% of patients with NF1 develop MPNSTs
usually arising from pre-existing plexiform neurofibromas
(see Figure 1). The minimum histological examination in
order to establish diagnosis includes immunohistochem-
ical stains for desmin, myogenin, vimentin, S-100,
proliferative activity marker MIB-1 and potentially expres-
sion of p53, cerbB2, p27, p16 oncogenes or tumor
suppressor genes. Recent studies highlight the role of
TopoIIa and CD117-overexpression in certain cases as
important markers for the potential administration of
TopoIIa inhibitors like etoposide and doxorubicin and
inhibitors of KIT-like imatinib mesylate (Gleevec) [6-8].
Radiotherapy provides local control and may delay the
onset of recurrence but has little effect on long term
survival. Chemotherapy has its own place in the treatment
of metastatic disease. Effective drugs include ifosfamide
and doxorubicin although carboplatin and etoposide have
been used with promising results in metastatic MPNST
refractory to first-line therapy [9]. Moreover, it may be
useful in the neo-adjuvant setting in order to achieve
tumor regression in patients with unresectable primaries.
In case 1, we analyzed our patient’s original tumor after
surgical excision with immunohistochemistry (see Table
1). The results correlated with recent studies suggesting
that expression of p53 plays an important role in the
evolution of MPNST from NF1 [10-12]. Furthermore, the
absence of immunohistochemical reaction against CD34
is in correlation with previous findings that its expression
seems to be lost during the process of MPNST formation
[12]. Interestingly, the lack of expression of TopoIIa could
explain the poor response to chemotherapy, in particular
to doxorubicin and etoposide (TopoIIa-targeting cytotoxic
drugs). More importantly, the administration of neo-
adjuvant chemotherapy resulted in evasion of amputation
and permitted a wide excision even though the removal of
the lesion was not with completely tumor-free margins.
Function of the limb was restored to normal and
subsequently performance status has increased signifi-
cantly, before patient’s deterioration and death as a result
of progression of the chest lesion.
In case 2, complete remission was achieved in our patient
after a multimodal approach. A successful surgical excision
of all lesions with tumor-free margins was feasible in the
first place and this approach remains the cornerstone of
management of MPNST. Chemotherapy with carboplatin
and etoposide provided no benefit in disease control
leading to SD. This is in contrast to a previous report,
showing promising results with this combination as first-
line therapy. A possible explanation for this lays in the fact
that immunohistochemistry ofourpatient’sbiopsy demon-
strated diffuse lack of expression of TopoIIa marker with
onlyfocal,positiveexpressionin10-20%ofneoplasticcells.
However, no data exist to date regarding any correlation
between TopoI or TopoIIa level of expression and drug
efficacy. The administration of ifosfamide plus doxorubicin
appeared favorable and should be considered as the
mainstay chemotherapeutic regimen of this disease as
pertains to other common soft tissue sarcomas. Moreover,
radiotherapy had an important role in improving local
control in the areas with minimal residual disease.
In conclusion, the currently described cases emphasize
that MPNSTs represent rare tumors that often occur in
patients with NF1. Surgical resection represents the
mainstay of treatment with consideration of neoadjuvant
chemotherapy pre-operatively in order to enhance resect-
ability [13]. Radiation and chemotherapy have a role in
selected patients with MPNST and anecdotal reports with
high-grade histology stress-out the potential benefits of
this treatment option [14,15]. There are many recent
advances in the understanding of the molecular pathogen-
esis of MPNST, which represent the best opportunities to
develop new strategies with targeted agents and che-
motherapy for the management of these patients [16-18].
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